Organisation paid for research Program year 2025 Source: CMS Open Payments

Celerion Lincoln

Neither a doctor nor a teaching hospital

Research payments

$18,128,640

15 payments

Through program year 2025, Celerion Lincoln is reported as receiving $18,128,640 in research payments, across 15 payments.

By program year

5 rows
Year Kind Amount Payments
2025 Research $1,348,345 2
2024 Research $793,879 1
2023 Research $8,436 2
2022 Research $9,266,887 4
2021 Research $6,711,092 6

Breakdown

Who paid Research payments · program years 2021–2025
  1. Vertex Pharmaceuticals Incorporated $18,128,640 15 payments
Studies the money was for Research payments · program years 2021–2025
  1. FIH HVs SAD, DDI, MAD, BA/FE cohort for new potentiator $6,372,144 3 payments
  2. A Phase 1, First-in-Human Study of Safety, Tolerability and Pharmacokinetics of VX-464 $6,347,234 3 payments
  3. An Open1 randomized double blind placebo controlled single dose Escalation Study evaluating the Safety and Pharmacokinetics of VX-708 in Healthy Subjects $1,138,147 1 payment
  4. A Phase 1, Open-label, Mass Balance Study to Investigate the Absorption, Distribution, Metabolism, and Excretion of 14C-VX-993 Following Single Oral Administration in Healthy Subjects $1,050,164 1 payment
  5. A Phase 1 Randomized Double-blind Placebo-controlled Single-dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-708 in Healthy Subjects $952,894 1 payment
  6. A Phase 1, Open-label, Randomized, Crossover Study to Evaluate the Relative Bioavailability and Food Effect of a Tablet and Suspension Formulation of VX-118 in Healthy Adult Subjects $793,879 1 payment
  7. A Phase 1, Open-label, Mass Balance Study to Investigate the Absorption, Distribution, Metabolism, and Excretion of 14C-VX-548 Following Single Administration in Healthy Subjects $601,692 2 payments
  8. VX-121 Ph1 ADME $574,251 1 payment
  9. A Phase 1, Open-label, Randomized, 2-part Study to Evaluate the Relative Bioavailability of Povetacicept Formulations and Bioequivalence of Povetacicept Presentations in Healthy Subjects $298,181 1 payment
  10. An Open-label Phase 1 Study to Examine the Effect of VX-814 on the Pharmacokinetics of Pitavastatin and Midazolam in Healthy Subjects $53 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record